Current Protein Identity:A0A0B4J1S8 New Search
Main Difference Dimensions in This Set
Different construct Different mutation/modification Different assembly state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics

Difference tags compare only the current result set; every original PDB and assembly record remains separate.

Related-Structure Differences

Each row represents one biological assembly in one PDB entry; multiple monomers of the same protein are listed separately.

PDB Entry Assembly / Oligomeric State Construct Mutations and Modifications Ligands, Ions and Non-polymers Experimental Method Experimental Conditions Structure Quality
2N73 Solution structure of the ACBD3:PI4KB complex Deposited 2015-09-02 Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric(2) Consistent with protein count
Chain B 5–80(76 aa) Fragment:UNP residues 5-80
Not recorded No recorded non-water small molecule SOLUTION NMR
NMR measurement conditions pH 6.5;298 K;Ionic strength (raw mmCIF value) 0.1;Pressure ambient
NMR sample composition 0.47 mM [U-13C; U-15N] protein_1, 0.47 mM [U-13C; U-15N] protein_2, 90% H2O/10% D2O | 90% H2O/10% D2O
Resolution not provided
5LX2 Lt 14-3-3 in complex with PI4KIIIB peptide Deposited 2016-09-19 Assembly 1 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric(4) Consistent with protein count
Chain B 304–309(6 aa) Fragment:UNP residues 304-309
Non-standard monomer:Yes (specific site not provided by mmCIF) No recorded non-water small molecule X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, SITTING DROP;291 K;MES, PEG 8000, ethylene glycol
Resolution 2.58 Å R-free 0.263
8Q6F HUMAN PI4KIIIB IN COMPLEX WITH COVALENTLY BOUND INHIBITOR (COMPOUND 4) Deposited 2023-08-11 Assembly 1 Insufficient information Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 531–828(298 aa)
Mutation:R409Q,R412Q KHR 3-(3-fluorosulfonyloxy-4-methoxy-phenyl)-2,5-dimethyl-7-(pyridin-4-ylmethylamino)pyrazolo[1,5-a]pyrimidine × 1 MG MAGNESIUM ION × 1 EDO 1,2-ETHANEDIOL × 7 GOL GLYCEROL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7;293 K;Sodium Formate
Resolution 1.51 Å R-free 0.224
8Q6G HUMAN PI4KIIIB IN COMPLEX WITH COVALENTLY BOUND INHIBITOR (COMPOUND 8) Deposited 2023-08-11 Assembly 1 Insufficient information Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 531–828(298 aa)
Mutation:R409Q,R412Q KIH 3-(3,4-dimethoxyphenyl)-7-[(4-fluorosulfonyloxyphenyl)methylamino]-2,5-dimethyl-pyrazolo[1,5-a]pyrimidine × 1 MG MAGNESIUM ION × 1 EDO 1,2-ETHANEDIOL × 3 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7;293 K;Sodium Formate
Resolution 1.54 Å R-free 0.221
8Q6H HUMAN PI4KIIIB IN COMPLEX WITH COVALENTLY BOUND INHIBITOR (COMPOUND 11) Deposited 2023-08-11 Assembly 1 Insufficient information Monomer;Protein × 1 PDB declaration: monomeric(1) Consistent with protein count
Chain A 531–828(298 aa)
Mutation:R409Q,R412Q MG MAGNESIUM ION × 1 KI7 3-(3-fluorosulfonyloxy-4-methoxy-phenyl)-7-[(4-fluorosulfonyloxyphenyl)methylamino]-2,5-dimethyl-pyrazolo[1,5-a]pyrimidine × 1 EDO 1,2-ETHANEDIOL × 1 X-RAY DIFFRACTION
X-ray crystallization conditions VAPOR DIFFUSION, HANGING DROP;pH 7;293 K;Sodium Formate
Resolution 1.94 Å R-free 0.237